Transgene: presents vaccine results at AACR
New Phase I immunological data confirm the strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
All treated patients are still in remission after a median follow-up of 18.6 months. The Phase II clinical trial will start in the coming weeks.
TG4050 is based on Transgene's myvac® platform and benefits from NEC's Artificial Intelligence (AI) technologies for the identification and prediction of the most immunogenic neoantigens.
Dr. Alessandro Riva, Chairman and CEO of Transgene, commented: "Almost all patients develop a specific immune response against the target antigens we have selected, reinforcing the proof-of-principle of our lead candidate. TG4050 is already demonstrating a beneficial effect in patients with head and neck cancers at high risk of relapse'.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction